|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:sunitinib
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:clinical_trial
|
around 60%
oncology
Phase III
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to sunitinib
|
|
gptkbp:discontinued
|
gptkb:battle
|
|
gptkbp:dosage_form
|
gptkb:beer
50 mg once daily
|
|
gptkbp:education
|
important for understanding treatment
|
|
gptkbp:effective_date
|
gptkb:2006
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:financial_products
|
D B01280
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sutent
|
|
gptkbp:ingredients
|
gptkb:sunitinib
C22 H26 F N3 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
L01 X E03
|
|
gptkbp:is_used_for
|
treatment of kidney cancer
treatment of gastrointestinal stromal tumors
|
|
gptkbp:lifespan
|
40-60 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
adults
|
|
gptkbp:provides_information_on
|
available for use
|
|
gptkbp:research_areas
|
cancer therapy
|
|
gptkbp:safety_features
|
required during treatment
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
cardiovascular events
high blood pressure
skin rash
thrombocytopenia
neutropenia
hemorrhage
thyroid dysfunction
mouth sores
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
gptkb:VEGFR
gptkb:PDGFR
KIT
CS F1 R
|
|
gptkbp:treatment
|
gptkb:battle
possible
|
|
gptkbp:type_of_care
|
important for efficacy
|